Sun Moon Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 23-10-2024
- Paid Up Capital ₹ 0.10 M
as on 23-10-2024
- Company Age 24 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 10.18 Cr
as on 23-10-2024
- Satisfied Charges ₹ 8.80 M
as on 23-10-2024
- Revenue -4.20%
(FY 2023)
- Profit 239.38%
(FY 2023)
- Ebitda 174.48%
(FY 2023)
- Net Worth 4.23%
(FY 2023)
- Total Assets 17.69%
(FY 2023)
About Sun Moon Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹10.18 Cr. The company has closed loans amounting to ₹8.80 M, as per Ministry of Corporate Affairs (MCA) records.
Amarnath Upadhyay and Santoshkumar Upadhyay serve as directors at the Company.
- CIN/LLPIN
U24230MH2000PTC126022
- Company No.
126022
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Apr 2000
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationBoisar, Maharashtra
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Sun Moon Pharmaceuticals Private Limited offer?
Sun Moon Pharmaceuticals Private Limited offers a wide range of products and services, including Pharma Ingredients & Raw Materials, Pyridine Derivatives.
Who are the key members and board of directors at Sun Moon Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amarnath Upadhyay  | Director | 20-Apr-2000 | Current |
| Santoshkumar Upadhyay | Director | 19-Nov-2005 | Current |
Financial Performance of Sun Moon Pharmaceuticals.
Sun Moon Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.2% decrease. The company also saw a substantial improvement in profitability, with a 239.38% increase in profit. The company's net worth moved up by a moderate rise of 4.23%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sun Moon Pharmaceuticals?
In 2023, Sun Moon Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 10 Nov 2023 | ₹6.18 Cr | Open |
Others Creation Date: 01 May 2022 | ₹4.00 Cr | Open |
Others Creation Date: 20 Sep 2021 | ₹0.80 M | Satisfied |
How Many Employees Work at Sun Moon Pharmaceuticals?
Sun Moon Pharmaceuticals has a workforce of 21 employees as of Mar 31, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sun Moon Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sun Moon Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
